BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, Lee SH, Park WS, Yoo NJ, Lee JY. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS. 2005;113:264-268. [PMID: 15865607 DOI: 10.1111/j.1600-0463.2005.apm_04.x] [Cited by in Crossref: 217] [Cited by in F6Publishing: 196] [Article Influence: 12.8] [Reference Citation Analysis]
Number Citing Articles
1 Korkmaz IN, Özdemir H. Synthesis and Anticancer Potential of New Hydroxamic Acid Derivatives as Chemotherapeutic Agents. Appl Biochem Biotechnol 2022. [PMID: 35917102 DOI: 10.1007/s12010-022-04107-z] [Reference Citation Analysis]
2 Zhang K, Wang J, Zhu Y, Liu X, Li J, Shi Z, Cao M, Li Y. Identification of Hub Genes Associated With the Development of Stomach Adenocarcinoma by Integrated Bioinformatics Analysis. Front Oncol 2022;12:844990. [PMID: 35686089 DOI: 10.3389/fonc.2022.844990] [Reference Citation Analysis]
3 Zhao W, Jiang X, Weisenthal K, Ma J, Botticelli EM, Zhou Y, Hedley-whyte ET, Wang B, Swearingen B, Soberman RJ, Klibanski A, Zhang X. High Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors. Front Oncol 2022;12:875122. [DOI: 10.3389/fonc.2022.875122] [Reference Citation Analysis]
4 Bouyahya A, El Hachlafi N, Aanniz T, Bourais I, Mechchate H, Benali T, Shariati MA, Burkov P, Lorenzo JM, Wilairatana P, Mubarak MS, El Omari N. Natural Bioactive Compounds Targeting Histone Deacetylases in Human Cancers: Recent Updates. Molecules 2022;27:2568. [PMID: 35458763 DOI: 10.3390/molecules27082568] [Reference Citation Analysis]
5 Adewole K, Ishola A, Olaoye I. In silico profiling of histone deacetylase inhibitory activity of compounds isolated from Cajanus cajan. Beni-Suef Univ J Basic Appl Sci 2022;11. [DOI: 10.1186/s43088-021-00191-y] [Reference Citation Analysis]
6 Avci E, Sarvari P, Savai R, Seeger W, Pullamsetti SS. Epigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets? Int J Mol Sci 2022;23:546. [PMID: 35008971 DOI: 10.3390/ijms23010546] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mao P, He W, Mai X, Feng L, Li N, Liao Y, Zhu C, Li J, Chen T, Liu S, Zhang Q, He L. Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors. Bioorganic & Medicinal Chemistry 2021. [DOI: 10.1016/j.bmc.2021.116599] [Reference Citation Analysis]
8 Silva LC, Borgato GB, Wagner VP, Martins MD, Rocha GZ, Lopes MA, Santos-Silva AR, de Castro Júnior G, Kowalski LP, Nor JE, Squarize CH, Castilho RM, Vargas PA. Cephaeline is an inductor of histone H3 acetylation and inhibitor of mucoepidermoid carcinoma cancer stem cells. J Oral Pathol Med 2021. [PMID: 34661317 DOI: 10.1111/jop.13252] [Reference Citation Analysis]
9 Dewaker V, Srivastava PN, Verma S, Srivastava AK, Prabhakar YS. Non-bonding energy directed designing of HDAC2 inhibitors through molecular dynamics simulation. J Biomol Struct Dyn 2021;:1-24. [PMID: 34662251 DOI: 10.1080/07391102.2021.1989037] [Reference Citation Analysis]
10 Bai M, Cui M, Li M, Yao X, Wu Y, Zheng L, Sun L, Song Q, Wang S, Liu L, Yu C, Huang Y. Discovery of a novel HDACi structure that inhibits the proliferation of ovarian cancer cells in vivo and in vitro. Int J Biol Sci 2021;17:3493-507. [PMID: 34512161 DOI: 10.7150/ijbs.62339] [Reference Citation Analysis]
11 Krishna A, Singh V, Singh S, Kumar S, Kumar V, Mehrotra D, Singh US, Mahdi AA. Upregulated histone deacetylase 2 gene correlates with the progression of oral squamous cell carcinoma. Cancer Biomark 2020;29:543-52. [PMID: 32865179 DOI: 10.3233/CBM-190729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Goutas D, Theocharis S, Tsourouflis G. Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia. Diagnostics (Basel) 2021;11:1346. [PMID: 34441281 DOI: 10.3390/diagnostics11081346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Chen L, Fei Y, Zhao Y, Chen Q, Chen P, Pan L. Expression and prognostic analyses of HDACs in human gastric cancer based on bioinformatic analysis. Medicine (Baltimore) 2021;100:e26554. [PMID: 34232196 DOI: 10.1097/MD.0000000000026554] [Reference Citation Analysis]
14 Shetty MG, Pai P, Deaver RE, Satyamoorthy K, Babitha KS. Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy. Pharmacol Res 2021;170:105695. [PMID: 34082029 DOI: 10.1016/j.phrs.2021.105695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Mustafa M, Abd El-Hafeez AA, Abdelhamid D, Katkar GD, Mostafa YA, Ghosh P, Hayallah AM, Abuo-Rahma GEA. A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles. Eur J Med Chem 2021;222:113569. [PMID: 34111829 DOI: 10.1016/j.ejmech.2021.113569] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 El-Sayed A, Aleya L, Kamel M. The link among microbiota, epigenetics, and disease development. Environ Sci Pollut Res Int 2021;28:28926-64. [PMID: 33860421 DOI: 10.1007/s11356-021-13862-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Tavares MT, de Almeida LC, Kronenberger T, Monteiro Ferreira G, Fujii de Divitiis T, Franco Zannini Junqueira Toledo M, Mariko Aymoto Hassimotto N, Agostinho Machado-Neto J, Veras Costa-Lotufo L, Parise-Filho R. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors. Bioorg Med Chem 2021;35:116085. [PMID: 33668008 DOI: 10.1016/j.bmc.2021.116085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Pouloudi D, Manou M, Sarantis P, Tsoukalas N, Tsourouflis G, Dana E, Karamouzis MV, Klijanienko J, Theocharis S. Clinical Significance of Histone Deacetylase (HDAC)-1, -2, -4 and -6 Expression in Salivary Gland Tumors. Diagnostics (Basel) 2021;11:517. [PMID: 33799478 DOI: 10.3390/diagnostics11030517] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
19 Gediya P, Parikh PK, Vyas VK, Ghate MD. Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders. Eur J Med Chem 2021;216:113332. [PMID: 33714914 DOI: 10.1016/j.ejmech.2021.113332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Mastoraki A, Schizas D, Charalampakis N, Naar L, Ioannidi M, Tsilimigras D, Sotiropoulou M, Moris D, Vassiliu P, Felekouras E. Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma. Mol Diagn Ther 2020;24:175-84. [PMID: 32125662 DOI: 10.1007/s40291-020-00454-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
21 Ansari I, Chaturvedi A, Chitkara D, Singh S. CRISPR/Cas mediated epigenome editing for cancer therapy. Semin Cancer Biol 2021:S1044-579X(20)30278-9. [PMID: 33421620 DOI: 10.1016/j.semcancer.2020.12.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Bhagat SD, Chanchal A, Gujrati M, Banerjee A, Mishra RK, Srivastava A. Implantable HDAC-inhibiting chemotherapeutics derived from hydrophobic amino acids for localized anticancer therapy. Biomater Sci 2021;9:261-71. [PMID: 33196720 DOI: 10.1039/d0bm01417f] [Reference Citation Analysis]
23 Park C, Oh I, Choi J, Ko S, Ahn J. Improved Prediction of Cancer Outcome Using Graph-Embedded Generative Adversarial Networks. IEEE Access 2021;9:20076-88. [DOI: 10.1109/access.2021.3054894] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Wang L, Zhang C, Hong Y, Li X, Li T, Gao A, Pan S, Liu B, Jin H, Cui D. Integrating Epigenetic Modulators in Nanofibers for Synergistic Gastric Cancer Therapy via Epigenetic Reprogramming. Nano Lett 2021;21:298-307. [PMID: 33356327 DOI: 10.1021/acs.nanolett.0c03665] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Xie Y, Tang P, Xing X, Zhao Y, Cao S, Liu S, Lu X, Zhong L. In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy. Spectrochim Acta A Mol Biomol Spectrosc 2020;241:118669. [PMID: 32653824 DOI: 10.1016/j.saa.2020.118669] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Ganai SA, Sheikh FA, Baba ZA. Plant flavone Chrysin as an emerging histone deacetylase inhibitor for prosperous epigenetic-based anticancer therapy. Phytother Res 2021;35:823-34. [PMID: 32930436 DOI: 10.1002/ptr.6869] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Akone SH, Ntie-Kang F, Stuhldreier F, Ewonkem MB, Noah AM, Mouelle SEM, Müller R. Natural Products Impacting DNA Methyltransferases and Histone Deacetylases. Front Pharmacol 2020;11:992. [PMID: 32903500 DOI: 10.3389/fphar.2020.00992] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
28 Kulka LAM, Fangmann PV, Panfilova D, Olzscha H. Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease. Front Cell Dev Biol 2020;8:425. [PMID: 32582706 DOI: 10.3389/fcell.2020.00425] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
29 Kwon DH, Ryu J, Kim YK, Kook H. Roles of Histone Acetylation Modifiers and Other Epigenetic Regulators in Vascular Calcification. Int J Mol Sci 2020;21:E3246. [PMID: 32375326 DOI: 10.3390/ijms21093246] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
30 Liu T, Wan Y, Xiao Y, Xia C, Duan G. Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy. J Med Chem 2020;63:8977-9002. [PMID: 32320239 DOI: 10.1021/acs.jmedchem.0c00491] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
31 Sun I, Yoon HY, Lim D, Kim K. Recent Trends in In Situ Enzyme-Activatable Prodrugs for Targeted Cancer Therapy. Bioconjugate Chem 2020;31:1012-24. [DOI: 10.1021/acs.bioconjchem.0c00082] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
32 Zhao H, Wang Y, Yang C, Zhou J, Wang L, Yi K, Li Y, Wang Q, Shi J, Kang C, Zeng L. EGFR-vIII downregulated H2AZK4/7AC though the PI3K/AKT-HDAC2 axis to regulate cell cycle progression. Clin Transl Med 2020;9:10. [PMID: 31993801 DOI: 10.1186/s40169-020-0260-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
33 V Stoddard S, Dodson K, Adams K, L Watkins D. In silico Design of Novel Histone Deacetylase 4 Inhibitors: Design Guidelines for Improved Binding Affinity. Int J Mol Sci 2019;21:E219. [PMID: 31905609 DOI: 10.3390/ijms21010219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
34 Kumboonma P, Saenglee S, Senawong T, Phaosiri C. Histone Deacetylase Inhibitors and Antioxidants From the Root of Gluta usitata. Natural Product Communications 2019;14:1934578X1989537. [DOI: 10.1177/1934578x19895370] [Reference Citation Analysis]
35 Urdinguio RG, Lopez V, Bayón GF, Diaz de la Guardia R, Sierra MI, García-Toraño E, Perez RF, García MG, Carella A, Pruneda PC, Prieto C, Dmitrijeva M, Santamarina P, Belmonte T, Mangas C, Diaconu E, Ferrero C, Tejedor JR, Fernandez-Morera JL, Bravo C, Bueno C, Sanjuan-Pla A, Rodriguez RM, Suarez-Alvarez B, López-Larrea C, Bernal T, Colado E, Balbín M, García-Suarez O, Chiara MD, Sáenz-de-Santa-María I, Rodríguez F, Pando-Sandoval A, Rodrigo L, Santos L, Salas A, Vallejo-Díaz J, C Carrera A, Rico D, Hernández-López I, Vayá A, Ricart JM, Seto E, Sima-Teruel N, Vaquero A, Valledor L, Cañal MJ, Pisano D, Graña-Castro O, Thomas T, Voss AK, Menéndez P, Villar-Garea A, Deutzmann R, Fernandez AF, Fraga MF. Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment. Nucleic Acids Res 2019;47:5016-37. [PMID: 30923829 DOI: 10.1093/nar/gkz195] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
36 Du Y, Lin J, Zhang R, Yang W, Quan H, Zang L, Han Y, Li B, Sun H, Wu J. Ubiquitin specific peptidase 5 promotes ovarian cancer cell proliferation through deubiquitinating HDAC2. Aging (Albany NY) 2019;11:9778-93. [PMID: 31727867 DOI: 10.18632/aging.102425] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
37 Smit KN, Jager MJ, de Klein A, Kiliҫ E. Uveal melanoma: Towards a molecular understanding. Prog Retin Eye Res 2020;75:100800. [PMID: 31563544 DOI: 10.1016/j.preteyeres.2019.100800] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
38 Xiong K, Zhang H, Du Y, Tian J, Ding S. Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer. Exp Mol Med 2019;51:1-15. [PMID: 31451695 DOI: 10.1038/s12276-019-0301-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
39 Chiu YH, Lee YY, Huang KC, Liu CC, Lin CS. Dovitinib Triggers Apoptosis and Autophagic Cell Death by Targeting SHP-1/p-STAT3 Signaling in Human Breast Cancers. J Oncol 2019;2019:2024648. [PMID: 31485222 DOI: 10.1155/2019/2024648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
40 Conte M, Dell'Aversana C, Sgueglia G, Carissimo A, Altucci L. HDAC2-dependent miRNA signature in acute myeloid leukemia. FEBS Lett 2019;593:2574-84. [PMID: 31254352 DOI: 10.1002/1873-3468.13521] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
41 Elmallah MIY, Micheau O. Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy. Cancers (Basel) 2019;11:E850. [PMID: 31248188 DOI: 10.3390/cancers11060850] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
42 Bedenbender K, Scheller N, Fischer S, Leiting S, Preissner KT, Schmeck BT, Vollmeister E. Inflammation-mediated deacetylation of the ribonuclease 1 promoter via histone deacetylase 2 in endothelial cells. FASEB J 2019;33:9017-29. [PMID: 31039328 DOI: 10.1096/fj.201900451R] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
43 Sanaei M, Kavoosi F. Effect of DNA Methyltransferase in Comparison to and in Combination with Histone Deacetylase Inhibitors on Hepatocellular Carcinoma HepG2 Cell Line. Asian Pac J Cancer Prev 2019;20:1119-25. [PMID: 31030484 DOI: 10.31557/APJCP.2019.20.4.1119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
44 Ishola AA, Adewole KE. Phytosterols and triterpenes from Morinda lucida Benth. exhibit binding tendency against class I HDAC and HDAC7 isoforms. Mol Biol Rep 2019;46:2307-25. [PMID: 30771146 DOI: 10.1007/s11033-019-04689-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
45 Tang W, Zhou W, Xiang L, Wu X, Zhang P, Wang J, Liu G, Zhang W, Peng Y, Huang X, Cai J, Bai Y, Bai L, Zhu W, Gu H, Xiong J, Ye C, Li A, Liu S, Wang J. The p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer. Nat Commun. 2019;10:663. [PMID: 30737378 DOI: 10.1038/s41467-018-08225-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 12.0] [Reference Citation Analysis]
46 Calcagno DQ, Wisnieski F, Mota ERDS, Maia de Sousa SB, Costa da Silva JM, Leal MF, Gigek CO, Santos LC, Rasmussen LT, Assumpção PP, Burbano RR, Smith MA. Role of histone acetylation in gastric cancer: implications of dietetic compounds and clinical perspectives. Epigenomics 2019;11:349-62. [DOI: 10.2217/epi-2018-0081] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
47 Fiedor E, Zajda K, Gregoraszczuk EL. Leptin Receptor Antagonists' Action on HDAC Expression Eliminating the Negative Effects of Leptin in Ovarian Cancer. Cancer Genomics Proteomics 2018;15:329-36. [PMID: 29976638 DOI: 10.21873/cgp.20091] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
48 Stoddard SV, May XA, Rivas F, Dodson K, Vijayan S, Adhika S, Parker K, Watkins DL. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8. Mol Inform 2019;38:e1800080. [PMID: 30369061 DOI: 10.1002/minf.201800080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
49 Orenay-Boyacioglu S, Kasap E, Gerceker E, Yuceyar H, Demirci U, Bilgic F, Korkmaz M. Expression profiles of histone modification genes in gastric cancer progression. Mol Biol Rep 2018;45:2275-82. [PMID: 30250993 DOI: 10.1007/s11033-018-4389-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
50 García-Domínguez DJ, Hontecillas-Prieto L, Rodríguez-Núñez P, Pascual-Pasto G, Vila-Ubach M, García-Mejías R, Robles MJ, Tirado OM, Mora J, Carcaboso AM, de Álava E. The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma. Oncotarget 2018;9:31397-410. [PMID: 30140378 DOI: 10.18632/oncotarget.25829] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
51 Matossian MD, Burks HE, Elliott S, Hoang VT, Bowles AC, Sabol RA, Bunnell BA, Martin EC, Burow ME, Collins-Burow BM. Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model. Oncoscience 2018;5:99-108. [PMID: 29854878 DOI: 10.18632/oncoscience.412] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
52 Stampone E, Caldarelli I, Zullo A, Bencivenga D, Mancini FP, Della Ragione F, Borriello A. Genetic and Epigenetic Control of CDKN1C Expression: Importance in Cell Commitment and Differentiation, Tissue Homeostasis and Human Diseases. Int J Mol Sci 2018;19:E1055. [PMID: 29614816 DOI: 10.3390/ijms19041055] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
53 Kim IS, Kim H, Kim M, Kwon J, Kim E, Hwang H, Oh P, Lim ST, Sohn M, Kim DH, Jeong H. Synthesis and Evaluation of 2-[ 18 F]Fluoroethyltriazolesuberohydroxamine Acid for Histone Deacetylase in a Tumor Model as a Positron Emission Tomography Radiotracer. Cancer Biotherapy and Radiopharmaceuticals 2018;33:52-9. [DOI: 10.1089/cbr.2017.2320] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
54 Xie R, Li Y, Tang P, Yuan Q. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. European Journal of Medicinal Chemistry 2018;143:320-33. [DOI: 10.1016/j.ejmech.2017.08.041] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
55 Xu J, Sun J, Wang P, Ma X, Li S. Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug micellar carrier for anticancer drugs. J Drug Target 2018;26:448-57. [PMID: 29251528 DOI: 10.1080/1061186X.2017.1419355] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
56 Wei J, Wang Z, Wang Z, Yang Y, Fu C, Zhu J, Jiang D. MicroRNA-31 Function as a Suppressor Was Regulated by Epigenetic Mechanisms in Gastric Cancer. Biomed Res Int 2017;2017:5348490. [PMID: 29333444 DOI: 10.1155/2017/5348490] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
57 Chrun ES, Modolo F, Daniel FI. Histone modifications: A review about the presence of this epigenetic phenomenon in carcinogenesis. Pathology - Research and Practice 2017;213:1329-39. [DOI: 10.1016/j.prp.2017.06.013] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 10.0] [Reference Citation Analysis]
58 Gendarme M, Baumann J, Ignashkova TI, Lindemann RK, Reiling JH. Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1. Mol Biol Cell 2017;28:3756-72. [PMID: 29074567 DOI: 10.1091/mbc.E17-03-0176] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
59 Fedele P, Orlando L, Cinieri S. Targeting triple negative breast cancer with histone deacetylase inhibitors. Expert Opin Investig Drugs 2017;26:1199-206. [PMID: 28952409 DOI: 10.1080/13543784.2017.1386172] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
60 Luo S, Ma K, Zhu H, Wang S, Liu M, Zhang W, Liang S, Xu N. Molecular, biological characterization and drug sensitivity of chidamide-resistant non-small cell lung cancer cells. Oncol Lett 2017;14:6869-75. [PMID: 29344124 DOI: 10.3892/ol.2017.7060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
61 Kumar N, Tomar R, Pandey A, Tomar V, Singh VK, Chandra R. Preclinical evaluation and molecular docking of 1,3-benzodioxole propargyl ether derivatives as novel inhibitor for combating the histone deacetylase enzyme in cancer. Artif Cells Nanomed Biotechnol 2018;46:1288-99. [PMID: 28847179 DOI: 10.1080/21691401.2017.1369423] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
62 Zeeshan R, Mutahir Z. Cancer metastasis - tricks of the trade. Bosn J Basic Med Sci 2017;17:172-82. [PMID: 28278128 DOI: 10.17305/bjbms.2017.1908] [Cited by in Crossref: 12] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
63 Zhu BY, Shang BY, Du Y, Li Y, Li L, Xu XD, Zhen YS. A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis. Oncotarget. 2017;8:14748-14758. [PMID: 28107195 DOI: 10.18632/oncotarget.14714] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
64 Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci. 2017;18. [PMID: 28671573 DOI: 10.3390/ijms18071414] [Cited by in Crossref: 468] [Cited by in F6Publishing: 434] [Article Influence: 93.6] [Reference Citation Analysis]
65 Liang X, Yuan X, Yu J, Wu Y, Li K, Sun C, Li S, Shen L, Kong F, Jia J, Björkholm M, Xu D. Histone Chaperone ASF1A Predicts Poor Outcomes for Patients With Gastrointestinal Cancer and Drives Cancer Progression by Stimulating Transcription of β-Catenin Target Genes. EBioMedicine 2017;21:104-16. [PMID: 28625518 DOI: 10.1016/j.ebiom.2017.06.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
66 Mari-Alexandre J, Diaz-Lagares A, Villalba M, Juan O, Crujeiras AB, Calvo A, Sandoval J. Translating cancer epigenomics into the clinic: focus on lung cancer. Transl Res 2017;189:76-92. [PMID: 28644958 DOI: 10.1016/j.trsl.2017.05.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
67 Webber LP, Wagner VP, Curra M, Vargas PA, Meurer L, Carrard VC, Squarize CH, Castilho RM, Martins MD. Hypoacetylation of acetyl-histone H3 (H3K9ac) as marker of poor prognosis in oral cancer. Histopathology 2017;71:278-86. [DOI: 10.1111/his.13218] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
68 Li R, Gan YH. Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Iβ Expression. Int J Mol Sci 2017;18:E1010. [PMID: 28481295 DOI: 10.3390/ijms18051010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
69 Zhao G, Wang G, Bai H, Li T, Gong F, Yang H, Wen J, Wang W. Targeted inhibition of HDAC8 increases the doxorubicin sensitivity of neuroblastoma cells via up regulation of miR-137. Eur J Pharmacol 2017;802:20-6. [PMID: 28223126 DOI: 10.1016/j.ejphar.2017.02.035] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
70 Kumboonma P, Senawong T, Saenglee S, Yenjai C, Phaosiri C. Identification of phenolic compounds from Zingiber offinale and their derivatives as histone deacetylase inhibitors and antioxidants. Med Chem Res 2017;26:650-61. [DOI: 10.1007/s00044-017-1785-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
71 Sunami Y, Araki M, Kan S, Ito A, Hironaka Y, Imai M, Morishita S, Ohsaka A, Komatsu N. Histone Acetyltransferase p300/CREB-binding Protein-associated Factor (PCAF) Is Required for All-trans-retinoic Acid-induced Granulocytic Differentiation in Leukemia Cells. J Biol Chem 2017;292:2815-29. [PMID: 28053092 DOI: 10.1074/jbc.M116.745398] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
72 Wei R, Zhao M, Zheng CH, Zhao M, Xia J. Concordance between somatic copy number loss and down-regulated expression: A pan-cancer study of cancer predisposition genes. Sci Rep 2016;6:37358. [PMID: 27929028 DOI: 10.1038/srep37358] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
73 Li L, Mei DT, Zeng Y. HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin. Biomedicine & Pharmacotherapy 2016;84:284-90. [DOI: 10.1016/j.biopha.2016.09.030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
74 Roos WP, Krumm A. The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair. Nucleic Acids Res 2016;44:10017-30. [PMID: 27738139 DOI: 10.1093/nar/gkw922] [Cited by in Crossref: 18] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
75 Wang J, Lv Q, Li X, Liu Y, Liu K, Wang H. Post-transcriptional and translational regulation modulates gene co-expression behavior in more synchronized pace to carry out molecular function in the cell. Gene 2016;587:163-8. [PMID: 27150569 DOI: 10.1016/j.gene.2016.04.055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
76 Debnath S, Debnath T, Majumdar S, Arunasree MK, Aparna V. A combined pharmacophore modeling, 3D QSAR, virtual screening, molecular docking, and ADME studies to identify potential HDAC8 inhibitors. Med Chem Res 2016;25:2434-50. [DOI: 10.1007/s00044-016-1652-5] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
77 Reis AHO, Vargas FR, Lemos B. Biomarkers of genome instability and cancer epigenetics. Tumor Biol 2016;37:13029-38. [DOI: 10.1007/s13277-016-5278-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
78 Tie J, Zhang X, Fan D. Epigenetic roles in the malignant transformation of gastric mucosal cells. Cell Mol Life Sci 2016;73:4599-610. [PMID: 27464701 DOI: 10.1007/s00018-016-2308-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
79 Chen H, Xie GH, Wang WW, Yuan XL, Xing WM, Liu HJ, Chen J, Dou M, Shen LS. Epigenetically downregulated Semaphorin 3E contributes to gastric cancer. Oncotarget 2015;6:20449-65. [PMID: 26036259 DOI: 10.18632/oncotarget.3936] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
80 Abshiru N, Rajan RE, Verreault A, Thibault P. Unraveling Site-Specific and Combinatorial Histone Modifications Using High-Resolution Mass Spectrometry in Histone Deacetylase Mutants of Fission Yeast. J Proteome Res 2016;15:2132-42. [PMID: 27223649 DOI: 10.1021/acs.jproteome.5b01156] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
81 Ansari J, Shackelford RE, El-Osta H. Epigenetics in non-small cell lung cancer: from basics to therapeutics. Transl Lung Cancer Res 2016;5:155-71. [PMID: 27186511 DOI: 10.21037/tlcr.2016.02.02] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 11.7] [Reference Citation Analysis]
82 Yoon S, Eom GH. HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Med J 2016;52:1-11. [PMID: 26865995 DOI: 10.4068/cmj.2016.52.1.1] [Cited by in Crossref: 168] [Cited by in F6Publishing: 163] [Article Influence: 28.0] [Reference Citation Analysis]
83 Brozek-pluska B, Kopeć M, Abramczyk H. Development of a new diagnostic Raman method for monitoring epigenetic modifications in the cancer cells of human breast tissue. Anal Methods 2016;8:8542-53. [DOI: 10.1039/c6ay02559e] [Cited by in Crossref: 34] [Article Influence: 5.7] [Reference Citation Analysis]
84 Frycz BA, Murawa D, Borejsza-Wysocki M, Wichtowski M, Spychała A, Marciniak R, Murawa P, Drews M, Jagodziński PP. Transcript level of AKR1C3 is down-regulated in gastric cancer. Biochem Cell Biol 2016;94:138-46. [PMID: 27019068 DOI: 10.1139/bcb-2015-0096] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
85 Noor Z, Afzal N, Rashid S. Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays. PLoS One 2015;10:e0139588. [PMID: 26431201 DOI: 10.1371/journal.pone.0139588] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
86 Ler SY, Leung CH, Khin LW, Lu GD, Salto-Tellez M, Hartman M, Iau PT, Yap CT, Hooi SC. HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population. Oncol Rep 2015;34:2238-50. [PMID: 26352599 DOI: 10.3892/or.2015.4263] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
87 Daniel M, Tollefsbol TO. Epigenetic linkage of aging, cancer and nutrition. J Exp Biol 2015;218:59-70. [PMID: 25568452 DOI: 10.1242/jeb.107110] [Cited by in Crossref: 88] [Cited by in F6Publishing: 70] [Article Influence: 12.6] [Reference Citation Analysis]
88 Jin K, Li S, Li X, Zhang J, Xu W, Li X. Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors. Bioorganic & Medicinal Chemistry 2015;23:4728-36. [DOI: 10.1016/j.bmc.2015.05.048] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
89 Padige G, Negmeldin AT, Pflum MK. Development of an ELISA-Based HDAC Activity Assay for Characterization of Isoform-Selective Inhibitors. J Biomol Screen 2015;20:1277-85. [PMID: 26232305 DOI: 10.1177/1087057115598118] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
90 Yan-Fang T, Zhi-Heng L, Li-Xiao X, Fang F, Jun L, Gang L, Lan C, Na-Na W, Xiao-Juan D, Li-Chao S, Wen-Li Z, Pei-Fang X, He Z, Guang-Hao S, Yan-Hong L, Yi-Ping L, Yun-Yun X, Hui-Ting Z, Yi W, Mei-Fang J, Lin L, Jian N, Shao-Yan H, Xue-Ming Z, Xing F, Jian W, Jian P. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells. PLoS One 2015;10:e0126566. [PMID: 26176219 DOI: 10.1371/journal.pone.0126566] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
91 El Tawdy A, Amin I, Abdel Hay R, Rashed L, Gad Z. Assessment of Tissue Level of Histone Deactylase-2 (HDAC-2) in Patients With Mycosis Fungoides. J Cutan Med Surg 2016;20:40-3. [PMID: 26033703 DOI: 10.1177/1203475415589055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
92 Paul S, Giri AK. Epimutagenesis: A prospective mechanism to remediate arsenic-induced toxicity. Environ Int 2015;81:8-17. [PMID: 25898228 DOI: 10.1016/j.envint.2015.04.002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 5.9] [Reference Citation Analysis]
93 Chun P. Histone deacetylase inhibitors in hematological malignancies and solid tumors. Arch Pharm Res 2015;38:933-49. [PMID: 25653088 DOI: 10.1007/s12272-015-0571-1] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 9.9] [Reference Citation Analysis]
94 Belcheva A, Irrazabal T, Martin A. Gut microbial metabolism and colon cancer: Can manipulations of the microbiota be useful in the management of gastrointestinal health? BioEssays 2015;37:403-12. [DOI: 10.1002/bies.201400204] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
95 Shan X, Fu YS, Aziz F, Wang XQ, Yan Q, Liu JW. Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation. PLoS One 2014;9:e115401. [PMID: 25521755 DOI: 10.1371/journal.pone.0115401] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 6.3] [Reference Citation Analysis]
96 Qi YF, Huang YX, Dong Y, Zheng LH, Bao YL, Sun LG, Wu Y, Yu CL, Jiang HY, Li YX. Systematic analysis of time-series gene expression data on tumor cell-selective apoptotic responses to HDAC inhibitors. Comput Math Methods Med 2014;2014:867289. [PMID: 25371703 DOI: 10.1155/2014/867289] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
97 Salvador LA, Park H, Al-Awadhi FH, Liu Y, Kim B, Zeller SL, Chen QY, Hong J, Luesch H. Modulation of Activity Profiles for Largazole-Based HDAC Inhibitors through Alteration of Prodrug Properties. ACS Med Chem Lett 2014;5:905-10. [PMID: 25147612 DOI: 10.1021/ml500170r] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
98 Wagner T, Brand P, Heinzel T, Krämer OH. Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis. Biochim Biophys Acta 2014;1846:524-38. [PMID: 25072962 DOI: 10.1016/j.bbcan.2014.07.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
99 Rahat B, Hamid A, Ahmad Najar R, Bagga R, Kaur J. Epigenetic mechanisms regulate placental c-myc and hTERT in normal and pathological pregnancies; c-myc as a novel fetal DNA epigenetic marker for pre-eclampsia. Molecular Human Reproduction 2014;20:1026-40. [DOI: 10.1093/molehr/gau053] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
100 Wisnieski F, Calcagno DQ, Leal MF, Chen ES, Gigek CO, Santos LC, Pontes TB, Rasmussen LT, Payão SL, Assumpção PP, Lourenço LG, Demachki S, Artigiani R, Burbano RR, Smith MC. Differential expression of histone deacetylase and acetyltransferase genes in gastric cancer and their modulation by trichostatin A. Tumour Biol 2014;35:6373-81. [PMID: 24668547 DOI: 10.1007/s13277-014-1841-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
101 Yu M, Salvador LA, Sy SK, Tang Y, Singh RS, Chen QY, Liu Y, Hong J, Derendorf H, Luesch H. Largazole pharmacokinetics in rats by LC-MS/MS. Mar Drugs 2014;12:1623-40. [PMID: 24658499 DOI: 10.3390/md12031623] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
102 Benedetti R, Conte M, Altucci L. Targeting Histone Deacetylases in Diseases: Where Are We? Antioxid Redox Signal 2015;23:99-126. [PMID: 24382114 DOI: 10.1089/ars.2013.5776] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 10.3] [Reference Citation Analysis]
103 Li J, Jin H, Wang X. Epigenetic biomarkers: potential applications in gastrointestinal cancers. ISRN Gastroenterol. 2014;2014:464015. [PMID: 24729878 DOI: 10.1155/2014/464015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
104 West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014;124:30-9. [PMID: 24382387 DOI: 10.1172/JCI69738] [Cited by in Crossref: 832] [Cited by in F6Publishing: 490] [Article Influence: 104.0] [Reference Citation Analysis]
105 Kunze MB, Wright DW, Werbeck ND, Kirkpatrick J, Coveney PV, Hansen DF. Loop interactions and dynamics tune the enzymatic activity of the human histone deacetylase 8. J Am Chem Soc 2013;135:17862-8. [PMID: 24171457 DOI: 10.1021/ja408184x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
106 Kwiecińska P, Wróbel A, Taubøll E, Gregoraszczuk EŁ. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells. Toxicol Lett 2014;224:225-32. [PMID: 24200999 DOI: 10.1016/j.toxlet.2013.10.035] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
107 Parbin S, Kar S, Shilpi A, Sengupta D, Deb M, Rath SK, Patra SK. Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem 2014;62:11-33. [PMID: 24051359 DOI: 10.1369/0022155413506582] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 7.7] [Reference Citation Analysis]
108 Vandermeers F, Neelature Sriramareddy S, Costa C, Hubaux R, Cosse J, Willems L. The role of epigenetics in malignant pleural mesothelioma. Lung Cancer 2013;81:311-8. [DOI: 10.1016/j.lungcan.2013.05.014] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
109 Ononye SN, VanHeyst MD, Oblak EZ, Zhou W, Ammar M, Anderson AC, Wright DL. Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors. ACS Med Chem Lett 2013;4:757-61. [PMID: 24900743 DOI: 10.1021/ml400158k] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 6.7] [Reference Citation Analysis]
110 Grassadonia A, Cioffi P, Simiele F, Iezzi L, Zilli M, Natoli C. Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. Cancers (Basel). 2013;5:919-942. [PMID: 24202327 DOI: 10.3390/cancers5030919] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
111 Chen YC, Huang WJ, Hsu JL, Yu CC, Wang WT, Guh JH. A novel hydroxysuberamide derivative potentiates MG132-mediated anticancer activity against human hormone refractory prostate cancers--the role of histone deacetylase and endoplasmic reticulum stress. Prostate 2013;73:1270-80. [PMID: 23813634 DOI: 10.1002/pros.22641] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
112 Fujii S, Okinaga T, Ariyoshi W, Takahashi O, Iwanaga K, Nishino N, Tominaga K, Nishihara T. Mechanisms of G1 cell cycle arrest and apoptosis in myeloma cells induced by hybrid-compound histone deacetylase inhibitor. Biochemical and Biophysical Research Communications 2013;434:413-20. [DOI: 10.1016/j.bbrc.2013.03.043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
113 Giudice FS, Pinto DS Jr, Nör JE, Squarize CH, Castilho RM. Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer. PLoS One 2013;8:e58672. [PMID: 23527004 DOI: 10.1371/journal.pone.0058672] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 8.8] [Reference Citation Analysis]
114 Noh JH, Chang YG, Kim MG, Jung KH, Kim JK, Bae HJ, Eun JW, Shen Q, Kim SJ, Kwon SH, Park WS, Lee JY, Nam SW. MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett. 2013;335:455-462. [PMID: 23499894 DOI: 10.1016/j.canlet.2013.03.003] [Cited by in Crossref: 80] [Cited by in F6Publishing: 86] [Article Influence: 8.9] [Reference Citation Analysis]
115 Bolden JE, Shi W, Jankowski K, Kan CY, Cluse L, Martin BP, MacKenzie KL, Smyth GK, Johnstone RW. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis. 2013;4:e519. [PMID: 23449455 DOI: 10.1038/cddis.2013.9] [Cited by in Crossref: 121] [Cited by in F6Publishing: 110] [Article Influence: 13.4] [Reference Citation Analysis]
116 Martins MD, Castilho RM. Histones: Controlling Tumor Signaling Circuitry. J Carcinog Mutagen 2013;1:1-12. [PMID: 25177526 DOI: 10.4172/2157-2518.S5-001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
117 Salvador LA, Luesch H. Discovery and mechanism of natural products as modulators of histone acetylation. Curr Drug Targets 2012;13:1029-47. [PMID: 22594471 DOI: 10.2174/138945012802008973] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
118 Gu Y, Yang P, Shao Q, Liu X, Xia S, Zhang M, Xu H, Shao Q. Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues. Oncol Lett. 2013;5:452-458. [PMID: 23420051 DOI: 10.3892/ol.2012.1057] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
119 Yun J, Johnson JL, Hanigan CL, Locasale JW. Interactions between epigenetics and metabolism in cancers. Front Oncol 2012;2:163. [PMID: 23162793 DOI: 10.3389/fonc.2012.00163] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 4.8] [Reference Citation Analysis]
120 Muñoz P, Iliou MS, Esteller M. Epigenetic alterations involved in cancer stem cell reprogramming. Mol Oncol 2012;6:620-36. [PMID: 23141800 DOI: 10.1016/j.molonc.2012.10.006] [Cited by in Crossref: 118] [Cited by in F6Publishing: 113] [Article Influence: 11.8] [Reference Citation Analysis]
121 Choi SE, Pflum MK. The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position. Bioorg Med Chem Lett 2012;22:7084-6. [PMID: 23089527 DOI: 10.1016/j.bmcl.2012.09.093] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
122 Gigek CO, Chen ES, Calcagno DQ, Wisnieski F, Burbano RR, Smith MA. Epigenetic mechanisms in gastric cancer. Epigenomics. 2012;4:279-294. [PMID: 22690664 DOI: 10.2217/epi.12.22] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 7.3] [Reference Citation Analysis]
123 Jung KH, Noh JH, Kim JK, Eun JW, Bae HJ, Xie HJ, Chang YG, Kim MG, Park H, Lee JY, Nam SW. HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. J Cell Biochem 2012;113:2167-77. [PMID: 22492270 DOI: 10.1002/jcb.24090] [Cited by in Crossref: 73] [Cited by in F6Publishing: 64] [Article Influence: 7.3] [Reference Citation Analysis]
124 Wang L, Xiang S, Williams KA, Dong H, Bai W, Nicosia SV, Khochbin S, Bepler G, Zhang X. Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. PLoS One 2012;7:e44265. [PMID: 22957056 DOI: 10.1371/journal.pone.0044265] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
125 Henrique R, Luís AS, Jerónimo C. The epigenetics of renal cell tumors: from biology to biomarkers. Front Genet 2012;3:94. [PMID: 22666228 DOI: 10.3389/fgene.2012.00094] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
126 Zafar SF, Nagaraju GP, El-Rayes B. Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma. Expert Opin Ther Targets 2012;16:707-18. [PMID: 22621256 DOI: 10.1517/14728222.2012.691473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
127 Sato A. Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects. Onco Targets Ther 2012;5:67-76. [PMID: 22573938 DOI: 10.2147/OTT.S23874] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
128 Min SK, Koh YH, Park Y, Kim HJ, Seo J, Park HR, Cho SJ, Kim IS. Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas. Korean J Pathol 2012;46:142-50. [PMID: 23109994 DOI: 10.4132/KoreanJPathol.2012.46.2.142] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
129 Labisso WL, Wirth M, Stojanovic N, Stauber RH, Schnieke A, Schmid RM, Krämer OH, Saur D, Schneider G. MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. Cell Cycle 2012;11:1593-602. [PMID: 22456335 DOI: 10.4161/cc.20008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
130 Regel I, Merkl L, Friedrich T, Burgermeister E, Zimmermann W, Einwächter H, Herrmann K, Langer R, Röcken C, Hofheinz R, Schmid R, Ebert MP. Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2. Gastroenterology 2012;143:99-109.e10. [PMID: 22465428 DOI: 10.1053/j.gastro.2012.03.035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
131 Yan W, Liu S, Xu E, Zhang J, Zhang Y, Chen X, Chen X. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene 2013;32:599-609. [PMID: 22391568 DOI: 10.1038/onc.2012.81] [Cited by in Crossref: 103] [Cited by in F6Publishing: 107] [Article Influence: 10.3] [Reference Citation Analysis]
132 Reichert N, Choukrallah M, Matthias P. Multiple roles of class I HDACs in proliferation, differentiation, and development. Cell Mol Life Sci 2012;69:2173-87. [DOI: 10.1007/s00018-012-0921-9] [Cited by in Crossref: 109] [Cited by in F6Publishing: 106] [Article Influence: 10.9] [Reference Citation Analysis]
133 Davies ER, Haitchi HM, Thatcher TH, Sime PJ, Kottmann RM, Ganesan A, Packham G, O'Reilly KM, Davies DE. Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis. Am J Respir Cell Mol Biol 2012;46:687-94. [PMID: 22246864 DOI: 10.1165/rcmb.2011-0040OC] [Cited by in Crossref: 38] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
134 Sun WJ, Zhou X, Zheng JH, Lu MD, Nie JY, Yang XJ, Zheng ZQ. Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis. Acta Biochim Biophys Sin (Shanghai) 2012;44:80-91. [PMID: 22194016 DOI: 10.1093/abbs/gmr113] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
135 Geutjes EJ, Bajpe PK, Bernards R. Targeting the epigenome for treatment of cancer. Oncogene 2012;31:3827-44. [PMID: 22139071 DOI: 10.1038/onc.2011.552] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
136 Noh JH, Jung KH, Kim JK, Eun JW, Bae HJ, Xie HJ, Chang YG, Kim MG, Park WS, Lee JY, Nam SW. Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS One 2011;6:e28103. [PMID: 22132221 DOI: 10.1371/journal.pone.0028103] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 6.0] [Reference Citation Analysis]
137 Zhang Y, Feng J, Jia Y, Xu Y, Liu C, Fang H, Xu W. Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group. European Journal of Medicinal Chemistry 2011;46:5387-97. [DOI: 10.1016/j.ejmech.2011.08.045] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
138 Samartzis N, Imesch P, Dedes KJ, Samartzis EP, Fedier A, Fink D, Caduff R, Fehr MK. Expression pattern of class I histone deacetylases in vulvar intraepithelial neoplasia and vulvar cancer: a tissue microarray study. BMC Cancer 2011;11:463. [PMID: 22029821 DOI: 10.1186/1471-2407-11-463] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
139 Chen C, Zhao M, Yin N, He B, Wang B, Yuan Y, Yu F, Hu J, Yin B, Lu Q. Abnormal histone acetylation and methylation levels in esophageal squamous cell carcinomas. Cancer Invest. 2011;29:548-556. [PMID: 21843048 DOI: 10.3109/07357907.2011.597810] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
140 Choi SE, Weerasinghe SV, Pflum MK. The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity. Bioorg Med Chem Lett 2011;21:6139-42. [PMID: 21889343 DOI: 10.1016/j.bmcl.2011.08.027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
141 Katto J, Mahlknecht U. Epigenetic regulation of cellular adhesion in cancer. Carcinogenesis 2011;32:1414-8. [PMID: 21705481 DOI: 10.1093/carcin/bgr120] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
142 Hong Y, Beckett C, Belyaev ND, Turner AJ. The impact of amyloid precursor protein signalling and histone deacetylase inhibition on neprilysin expression in human prostate cells. Int J Cancer 2012;130:775-86. [PMID: 21365649 DOI: 10.1002/ijc.26028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
143 Xu XS, Wang L, Abrams J, Wang G. Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer. J Hematol Oncol 2011;4:17. [PMID: 21507255 DOI: 10.1186/1756-8722-4-17] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
144 Alhosin M, Sharif T, Mousli M, Etienne-Selloum N, Fuhrmann G, Schini-Kerth VB, Bronner C. Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties. J Exp Clin Cancer Res 2011;30:41. [PMID: 21496237 DOI: 10.1186/1756-9966-30-41] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 6.7] [Reference Citation Analysis]
145 Zhang Y, Feng J, Jia Y, Wang X, Zhang L, Liu C, Fang H, Xu W. Development of Tetrahydroisoquinoline-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities. J Med Chem 2011;54:2823-38. [DOI: 10.1021/jm101605z] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 6.5] [Reference Citation Analysis]
146 Di Marcotullio L, Canettieri G, Infante P, Greco A, Gulino A. Protected from the inside: Endogenous histone deacetylase inhibitors and the road to cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2011;1815:241-52. [DOI: 10.1016/j.bbcan.2011.01.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 23] [Article Influence: 0.9] [Reference Citation Analysis]
147 Song Y, Shiota M, Tamiya S, Kuroiwa K, Naito S, Tsuneyoshi M. The significance of strong histone deacetylase 1 expression in the progression of prostate cancer. Histopathology. 2011;58:773-780. [PMID: 21438903 DOI: 10.1111/j.1365-2559.2011.03797.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
148 Zeglis BM, Pillarsetty N, Divilov V, Blasberg RA, Lewis JS. The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer. Nucl Med Biol 2011;38:683-96. [PMID: 21718944 DOI: 10.1016/j.nucmedbio.2010.12.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
149 Ren J, Singh BN, Huang Q, Li Z, Gao Y, Mishra P, Hwa YL, Li J, Dowdy SC, Jiang SW. DNA hypermethylation as a chemotherapy target. Cell Signal. 2011;23:1082-1093. [PMID: 21345368 DOI: 10.1016/j.cellsig.2011.02.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 6.5] [Reference Citation Analysis]
150 Thomas S, Thurn KT, Biçaku E, Marchion DC, Münster PN. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat. 2011;130:437-447. [PMID: 21298336 DOI: 10.1007/s10549-011-1364-y] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 6.1] [Reference Citation Analysis]
151 Mwakwari SC, Patil V, Guerrant W, Oyelere AK. Macrocyclic histone deacetylase inhibitors. Curr Top Med Chem 2010;10:1423-40. [PMID: 20536416 DOI: 10.2174/156802610792232079] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 5.8] [Reference Citation Analysis]
152 Gemoll T, Roblick UJ, Szymczak S, Braunschweig T, Becker S, Igl BW, Bruch HP, Ziegler A, Hellman U, Difilippantonio MJ, Ried T, Jörnvall H, Auer G, Habermann JK. HDAC2 and TXNL1 distinguish aneuploid from diploid colorectal cancers. Cell Mol Life Sci 2011;68:3261-74. [PMID: 21290163 DOI: 10.1007/s00018-011-0628-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
153 Hatziapostolou M, Iliopoulos D. Epigenetic aberrations during oncogenesis. Cell Mol Life Sci. 2011;68:1681-1702. [PMID: 21249513 DOI: 10.1007/s00018-010-0624-z] [Cited by in Crossref: 112] [Cited by in F6Publishing: 104] [Article Influence: 10.2] [Reference Citation Analysis]
154 Yagi Y, Fushida S, Harada S, Kinoshita J, Makino I, Oyama K, Tajima H, Fujita H, Takamura H, Ninomiya I, Fujimura T, Ohta T, Yashiro M, Hirakawa K. Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line. J Exp Clin Cancer Res 2010;29:149. [PMID: 21080974 DOI: 10.1186/1756-9966-29-149] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
155 Waby JS, Chirakkal H, Yu C, Griffiths GJ, Benson RS, Bingle CD, Corfe BM. Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. Mol Cancer 2010;9:275. [PMID: 20950428 DOI: 10.1186/1476-4598-9-275] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 5.8] [Reference Citation Analysis]
156 Yang X, Lay F, Han H, Jones PA. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci. 2010;31:536-546. [PMID: 20846732 DOI: 10.1016/j.tips.2010.08.001] [Cited by in Crossref: 208] [Cited by in F6Publishing: 191] [Article Influence: 17.3] [Reference Citation Analysis]
157 Hayashi A, Horiuchi A, Kikuchi N, Hayashi T, Fuseya C, Suzuki A, Konishi I, Shiozawa T. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int J Cancer 2010;127:1332-46. [PMID: 20049841 DOI: 10.1002/ijc.25151] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 7.4] [Reference Citation Analysis]
158 Adams H, Fritzsche FR, Dirnhofer S, Kristiansen G, Tzankov A. Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin’s lymphoma. Expert Opin Ther Targets. 2010;14:577-584. [PMID: 20415600 DOI: 10.1517/14728221003796609] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 4.4] [Reference Citation Analysis]
159 Lee KH, Choi EY, Kim MK, Kim KO, Jang BI, Kim SW, Kim SW, Song SK, Kim JR. Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer. Mol Cell Biochem 2010;343:163-71. [PMID: 20559690 DOI: 10.1007/s11010-010-0510-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
160 Paik PK, Krug LM. Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol 2010;5:275-9. [PMID: 20035240 DOI: 10.1097/JTO.0b013e3181c5e366] [Cited by in Crossref: 41] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
161 Gonzalo S. Epigenetic alterations in aging. J Appl Physiol (1985) 2010;109:586-97. [PMID: 20448029 DOI: 10.1152/japplphysiol.00238.2010] [Cited by in Crossref: 130] [Cited by in F6Publishing: 113] [Article Influence: 10.8] [Reference Citation Analysis]
162 Zhang Y, Feng J, Liu C, Zhang L, Jiao J, Fang H, Su L, Zhang X, Zhang J, Li M, Wang B, Xu W. Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors. Bioorganic & Medicinal Chemistry 2010;18:1761-72. [DOI: 10.1016/j.bmc.2010.01.060] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
163 Oehme I, Deubzer HE, Lodrini M, Milde T, Witt O. Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opin Investig Drugs 2009;18:1605-17. [PMID: 19780707 DOI: 10.1517/14728220903241658] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
164 Smith EM, Boyd K, Davies FE. The potential role of epigenetic therapy in multiple myeloma. Br J Haematol 2010;148:702-13. [PMID: 19912222 DOI: 10.1111/j.1365-2141.2009.07976.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
165 Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31:27-36. [PMID: 19752007 DOI: 10.1093/carcin/bgp220] [Cited by in Crossref: 1508] [Cited by in F6Publishing: 1360] [Article Influence: 116.0] [Reference Citation Analysis]
166 Mühlenberg T, Zhang Y, Wagner AJ, Grabellus F, Bradner J, Taeger G, Lang H, Taguchi T, Schuler M, Fletcher JA. Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res. 2009;69:6941-6950. [PMID: 19706776 DOI: 10.1158/0008-5472.can-08-4004] [Cited by in Crossref: 63] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
167 Marquard L, Poulsen CB, Gjerdrum LM, de Nully Brown P, Christensen IJ, Jensen PB, Sehested M, Johansen P, Ralfkiaer E. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology 2009;54:688-98. [PMID: 19438744 DOI: 10.1111/j.1365-2559.2009.03290.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 85] [Article Influence: 6.4] [Reference Citation Analysis]
168 Chang H, Chiang C, Hung H, Lin C, Deng Y, Kuo MY. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncology 2009;45:610-4. [DOI: 10.1016/j.oraloncology.2008.08.011] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 6.1] [Reference Citation Analysis]
169 Horiuchi M, Morinobu A, Chin T, Sakai Y, Kurosaka M, Kumagai S. Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2009;36:1580-9. [PMID: 19531758 DOI: 10.3899/jrheum.081115] [Cited by in Crossref: 84] [Cited by in F6Publishing: 73] [Article Influence: 6.5] [Reference Citation Analysis]
170 Han S, Lee JK. Anti-inflammatory effect of Trichostatin-A on murine bone marrow-derived macrophages. Arch Pharm Res 2009;32:613-24. [DOI: 10.1007/s12272-009-1418-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
171 Arkenau HT. Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J Cancer Res Clin Oncol 2009;135:855-66. [PMID: 19363621 DOI: 10.1007/s00432-009-0583-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 3.3] [Reference Citation Analysis]
172 Chowdhury S, Ammanamanchi S, Howell GM. Epigenetic Targeting of Transforming Growth Factor β Receptor II and Implications for Cancer Therapy. Mol Cell Pharmacol 2009;1:57-70. [PMID: 20414468 DOI: 10.4255/mcpharmacol.09.07] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
173 Cui W, Hu SX, Tang ZY, Hu KQ. In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice. Anticancer Drugs. 2008;19:891-897. [PMID: 18766003 DOI: 10.1097/CAD.0b013e32830ef8ca] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
174 Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008;53:267-77. [PMID: 18671804 DOI: 10.1111/j.0309-0167.2008.03109.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
175 Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008;53:267-77. [PMID: 18671804 DOI: 10.1111/j.0309-0167.2008.03109.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 45] [Article Influence: 0.2] [Reference Citation Analysis]
176 Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009;280:168-76. [PMID: 19103471 DOI: 10.1016/j.canlet.2008.10.047] [Cited by in Crossref: 262] [Cited by in F6Publishing: 255] [Article Influence: 18.7] [Reference Citation Analysis]
177 Fritzsche FR, Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, Scholman K, Denkert C, Dietel M. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer. 2008;8:381. [PMID: 19099586 DOI: 10.1186/1471-2407-8-381] [Cited by in Crossref: 111] [Cited by in F6Publishing: 110] [Article Influence: 7.9] [Reference Citation Analysis]
178 Abbas A, Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics 2008;3:300-9. [PMID: 19029799 DOI: 10.4161/epi.3.6.7273] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 6.1] [Reference Citation Analysis]
179 Cortez CC, Jones PA. Chromatin, cancer and drug therapies. Mutat Res 2008;647:44-51. [PMID: 18691602 DOI: 10.1016/j.mrfmmm.2008.07.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 3.6] [Reference Citation Analysis]
180 Marquard L, Petersen KD, Persson M, Hoff KD, Jensen PB, Sehested M. Monitoring the effect of belinostat in solid tumors by H4 acetylation. APMIS 2008;116:382-92. [PMID: 18452428 DOI: 10.1111/j.1600-0463.2008.00957.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
181 Bieliauskas AV, Pflum MK. Isoform-selective histone deacetylase inhibitors. Chem Soc Rev 2008;37:1402-13. [PMID: 18568166 DOI: 10.1039/b703830p] [Cited by in Crossref: 229] [Cited by in F6Publishing: 203] [Article Influence: 16.4] [Reference Citation Analysis]
182 Spurling CC, Godman CA, Noonan EJ, Rasmussen TP, Rosenberg DW, Giardina C. HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol Carcinog. 2008;47:137-147. [PMID: 17849419 DOI: 10.1002/mc.20373] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 5.2] [Reference Citation Analysis]
183 Lafon-Hughes L, Di Tomaso MV, Méndez-Acuña L, Martínez-López W. Chromatin-remodelling mechanisms in cancer. Mutat Res 2008;658:191-214. [PMID: 18403253 DOI: 10.1016/j.mrrev.2008.01.008] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 3.6] [Reference Citation Analysis]
184 Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409:581-9. [PMID: 17868033 DOI: 10.1042/BJ20070779] [Cited by in Crossref: 524] [Cited by in F6Publishing: 276] [Article Influence: 37.4] [Reference Citation Analysis]
185 Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C, Röcken C. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008;9:139-48. [PMID: 18207460 DOI: 10.1016/S1470-2045(08)70004-4] [Cited by in Crossref: 254] [Cited by in F6Publishing: 154] [Article Influence: 18.1] [Reference Citation Analysis]
186 Kanai Y. Overexpression of HDACs: a prognostic marker for gastric cancer identified by tissue microarray. The Lancet Oncology 2008;9:91-3. [DOI: 10.1016/s1470-2045(08)70012-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
187 Fog CK, Jensen KT, Lund AH. Chromatin-modifying proteins in cancer. APMIS 2007;115:1060-89. [PMID: 18042144 DOI: 10.1111/j.1600-0463.2007.apm_776.xml.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
188 Lah JJ, Cui W, Hu KQ. Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol 2007; 13(40): 5299-5305 [PMID: 17879397 DOI: 10.3748/wjg.v13.i40.5299] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 60] [Article Influence: 4.3] [Reference Citation Analysis]
189 Pluemsampant S, Safronova OS, Nakahama K, Morita I. Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors: Hypoxia Activates HDAC Via CK2. Int J Cancer 2008;122:333-41. [DOI: 10.1002/ijc.23094] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 5.1] [Reference Citation Analysis]
190 Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26:5420-5432. [PMID: 17694083 DOI: 10.1038/sj.onc.1210610] [Cited by in Crossref: 648] [Cited by in F6Publishing: 618] [Article Influence: 43.2] [Reference Citation Analysis]
191 Marwick JA, Ito K, Adcock IM, Kirkham PA. Oxidative stress and steroid resistance in asthma and COPD: pharmacological manipulation of HDAC-2 as a therapeutic strategy. Expert Opin Ther Targets 2007;11:745-55. [PMID: 17504013 DOI: 10.1517/14728222.11.6.745] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
192 Mehnert JM, Kelly WK. Histone deacetylase inhibitors: biology and mechanism of action. Cancer J 2007;13:23-9. [PMID: 17464243 DOI: 10.1097/PPO.0b013e31803c72ba] [Cited by in Crossref: 71] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
193 Menegola E, Di Renzo F, Broccia ML, Giavini E. Inhibition of histone deacetylase as a new mechanism of teratogenesis. Birth Defects Res C Embryo Today 2006;78:345-53. [PMID: 17315247 DOI: 10.1002/bdrc.20082] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
194 Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007;1:19-25. [PMID: 19383284 DOI: 10.1016/j.molonc.2007.01.001] [Cited by in Crossref: 542] [Cited by in F6Publishing: 525] [Article Influence: 36.1] [Reference Citation Analysis]
195 Huang L. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J Cell Physiol. 2006;209:611-616. [PMID: 17001696 DOI: 10.1002/jcp.20781] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 4.6] [Reference Citation Analysis]
196 Richon VM. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 2006;95:S2-6. [DOI: 10.1038/sj.bjc.6603463] [Cited by in Crossref: 139] [Cited by in F6Publishing: 58] [Article Influence: 8.7] [Reference Citation Analysis]
197 Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84. [DOI: 10.1038/nrd2133] [Cited by in Crossref: 2086] [Cited by in F6Publishing: 1940] [Article Influence: 130.4] [Reference Citation Analysis]
198 Liu T, Kuljaca S, Tee A, Marshall GM. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 2006;32:157-65. [PMID: 16516391 DOI: 10.1016/j.ctrv.2005.12.006] [Cited by in Crossref: 159] [Cited by in F6Publishing: 151] [Article Influence: 9.9] [Reference Citation Analysis]